Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial

Personalizing Radiotherapy in Ductal Carcinoma In Situ Using a 12-Gene Expression Assay: Insights from a Prospective Clinical Trial

This clinical trial prospectively evaluates how a 12-gene expression assay (DCIS score) guides postoperative radiotherapy decisions after breast-conserving surgery in ductal carcinoma in situ, showing tailored radiotherapy use may reduce ipsilateral breast events.
Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiotherapy alone, with limited toxicity.
Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT

Advancing Radiotherapy in High-Grade Glioma: Targeted Volume Reduction with Hypofractionated Simultaneous Boost IMRT

A randomized trial demonstrates that modified target delineation integrating multimodal MRI and white matter tractography with moderately hypofractionated radiotherapy achieves comparable survival outcomes to standard IMRT while reducing irradiation volumes in high-grade glioma patients.